Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 22Lung Neoplasms 10Stomach Neoplasms 9Neoplasm Metastasis 8Esophageal Neoplasms 7Breast Neoplasms 7Colorectal Neoplasms 6Nasopharyngeal Carcinoma 5Leukemia, Myeloid, Acute 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Esophageal Squamous Cell Carcinoma 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Urinary Bladder Neoplasms 2Rectal Neoplasms 2Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Head and Neck Neoplasms 2Glioma 2Glioblastoma 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Anatomic Stage II Breast Cancer AJCC v8 2

Interventions

trastuzumab biosimilar HLX02 2ribociclib 2pertuzumab 2Trastuzumab 2Taxes 2Specimen Handling 2Paclitaxel 2PF-05280014 2Ontruzant 2Ogivri 2Magnetic Resonance Spectroscopy 2Drug Therapy 2Docetaxel 22C4 antibody 2tucatinib 1exemestane 1durvalumab 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Mastectomy, Segmental 1Mastectomy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Fulvestrant 1Fluorodeoxyglucose F18 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anatomic Stage II Breast Cancer AJCC v8 × Drug Therapy × 90 days × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT05710328 2026-05-05

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
235 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡